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Abstract 
Background: In this review, we were interested to identify the wide universe of enzymes associated with epigenetic 
modifications, whose gene expression is regulated by miRNAs with a high relative abundance in Crohn’s disease (CD) 
affected tissues, with the aim to determine their impact in the pathogenesis and evolution of the disease.
Methods: We used HMDD and Bibliometrix R‑package in order to identify the miRNAs overexpressed in CD. The 
identified enzymes associated with epigenetic mechanisms and post‑translational modifications, regulated by miR‑
NAs upregulated in CD, were analyzed using String v11 database.
Results: We found 190 miRNAs with great abundance in patients with CD, of which 26 miRNAs regulate the gene 
expression of enzymes known to catalyze epigenetic modifications involved in essentials pathophysiological pro‑
cesses, such as chromatin architecture reorganization, immune response regulation including CD4+ T cells polariza‑
tion, integrity of gut mucosa, gut microbiota composition and tumorigenesis.
Conclusion: The integrated analysis of miRNAs with a high relative abundance in patients with CD showed a com‑
bined and superimposed gene expression regulation of enzymes associated with relevant epigenetic mechanisms 
and that could explain, in part, the pathogenesis of CD.
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Background
Crohn’s disease (CD) is a recurrent inflammatory bowel 
disease (IBD) that is increasing in prevalence worldwide. 
CD is thought to result from a combination of genetic, 
immune and environmental factors. In recent years, the 
intestinal microbiota has also been shown to play a role 
in the development of the pathology [1–3]. These fac-
tors can lead to inappropriate chronic activation of the 
mucosal immune response, often resulting in strictures 
or fistulas [4].
To obtain a better understanding of the underlying 
mechanisms of CD, it is important to investigate the 
molecular and genetic changes involved in the onset 
and chronification of the disease. Studies of gene expres-
sion have been carried out jointly in patients with CD 
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to identify gene expression profiles associated with 
adaptive immune response, cell adhesion, barrier integ-
rity and extracellular matrix remodeling [3, 5–7]. Gene 
expression is partly regulated by microRNAs (miRNAs), 
small non-coding RNAs that bind to the 3′ untranslated 
regions of target mRNAs and negatively regulate their 
stability or translation [8]. miRNAs have been found to 
be involved in several pathologies, such as cancer, auto-
immune disease, inflammatory disease including IBD, 
among others [9, 10]. Some studies focused on under-
standing the role of miRNAs in IBD, have described dif-
ferent miRNA expression profiles in patients with active 
or inactive disease, comparing with normal controls [11]. 
In CD, it has been demonstrated that single-nucleotide 
polymorphisms (SNPs) in miRNA binding sites may 
affect the expression of target mRNAs that are involved 
in the pathogenesis of the disease. In this regard, Brest 
et  al. have shown that a synonymous variant in IRGM 
gene affects a binding site of miR-196, resulting in dereg-
ulation of IRGM-dependent xenophagy in CD [12, 13]. 
Other researches have evidenced the association of spe-
cific IL-23R gene variant with IBD susceptibility, which 
could be explained by the IL-23R gene variant inability 
to bind to miRNAs Let-7e and Let-7f. The loss of miRNA 
regulation induces high levels of both IL23R mRNA and 
protein production, and it could contribute to disease 
chronification, through sustained IL-23R signaling [12–
14]. Thus, genetic research in IBD has made possible to 
identify several genetic factors; however, these factors 
only explain a small proportion of IBD complexity and 
variants. Epigenetic modifications of the genomic land-
scape studies and their association with identified genetic 
factors, open an interesting scenario that could explain 
the interactions between genes and environment, dis-
playing new knowledge about IBD pathogenesis [15].
Epigenetic modifications are defined as heritable 
changes in gene expression that are mitotically and/or 
meiotically heritable and that do not involve a change in 
DNA sequence [16]. Thus, epigenetics has a great influ-
ence in gene expression and function generating varieties 
in cell differentiation, morphogenesis and adaptability 
of an organism. These findings suggest that epigenetic 
mechanisms could connect genotype and environmen-
tal factors and thusly lead to phenotypical changes [17]. 
Epigenetic modifications, such as DNA methylations 
and histone modifications, have been evidenced to be 
implicated in carcinogenesis, psychiatric diseases, neu-
rodegenerative disorders, autoimmune and chronic 
inflammatory diseases [10, 15–21]. Regarding this mat-
ter, several studies have demonstrated the association 
of IBD susceptibility and pathogenesis with alterations 
in the methylation status of IBD-associated genes. DNA 
methylation generates changes in gene expression levels 
involved in immunological response regulation pathway, 
intestinal epithelial barrier integrity, stricture formation, 
among others, implicated in IBD pathogenesis [15, 22]. 
According to these findings, it is interesting to mention 
that in patients affected by ulcerative colitis (UC), an 
increased DNA methylation of Runt-related transcription 
factor 3 (RUNX3), Protease activated receptor 2 (PAR2) 
and E-cadherin genes have been found [23–25]. Addi-
tionally, colonic inflammation in IBD patients has shown 
association with colonic mucosal microbiota composi-
tion and DNA methylation patterns [26].
Histone methylation and acetylation have been less 
extensively studied in IBD. In ileal epithelial cells of newly 
diagnosed pediatric CD patients, it has been described an 
histone methylation pattern characterized by increased 
histone H3-lysine 4 trimethylation (H3K4me3) affect-
ing genes involved in cytokine functions and epithelial 
immune response and decreased H3K4me3 shown by 
genes associated with metabolism [20].
Regarding histone acetylation, in several human can-
cers, including colorectal carcinomas, histone dea-
cetylases (HDACs) expression levels have been found 
increased [27–30]. Interestingly, in experimental coli-
tis, HDAC inhibitors reduce colitis severity, suppress 
the secretion of pro-inflammatory cytokines, expand 
the number of Foxp3+ Regulatory T cells (Tregs) and 
enhance their suppressive function [31–33]. These find-
ings demonstrate that alterations in histone acetyl-
transferases (HATs) and HDAC expression are not only 
involved in neoplastic development, but also in inflam-
matory phenomenon. On this basis, it has been shown 
that the short chain fatty acid (SCFA) butyrate, an HDAC 
inhibitor produced by colonic commensal bacteria fer-
mentation of dietary fibers, induces in naïve CD4 + T 
cells, an increasing of histone H3 acetylation in the pro-
motor and conserved non-coding sequence regions of 
Forkhead box P3 (Foxp3) locus, promoting their dif-
ferentiation to Tregs [34, 35]. Additionally, propionate, 
another SCFA generated from gut bacterial fermentation, 
induces in colonic Tregs, an increased regulatory pheno-
type characterized by elevated Foxp3 expression and high 
secretion of the anti-inflammatory cytokine IL-10. Pro-
pionate improves the immunosuppressive functions of 
colonic Tregs by decreasing HDAC6 and HDAC9 levels, 
thereby enhancing histone acetylation, in a G-protein-
coupled receptor-mediated process [36]. Furthermore, 
in dendritic cells (DCs), the HDAC inhibitory activ-
ity of butyrate, downregulates Relb, transcription fac-
tor required for the activation and function of DCs, and 
induce a DCs phenotype that promotes the expression of 
Foxp3 in CD4+ T cells and therefore Treg cell differen-
tiation  [34]. Thus, these findings show that the SCFAs, 
metabolites generated in high amounts by the intestinal 
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microbiota, are capable of regulating the gut immune 
balance between pro- and anti-inflammatory processes 
via epigenetic mechanisms. In this regard, several stud-
ies show the relevance of the diet high in fiber and low 
in saturated fats to maintain the balance of the intestinal 
microbiota [37].
In this regard, analysis of gastrointestinal mucosal-
associated microbioma from IBD patients samples has 
shown a remarkable dysbiosis characterized by a decrease 
in butyrate-producing bacteria species, such as Rose-
buria intestinalis, Faecalibacterium prausnitzii, Eubac-
terium rectale and Butyricicoccus pullicaecorum; and an 
increase in species such as Escherichia coli, Fusobacte-
rium nucleatum, Haemophilus parainfluenzae, among 
others involved in inflammatory and tumorigenesis pro-
cesses [38, 39]. Likewise, the SCFAs concentration, in 
fecal samples of IBD patients, is also diminished, mainly 
the butyrate and acetate levels, in patients with active UC 
[40–42]. The etiology of dysbiosis in IBD patients is not 
clearly understood, but it is known that the IBD patients 
show an immunological response against the intestinal 
microbiota that induce a loss of the intestinal barrier 
integrity and the consequently microorganism infiltra-
tion. These events contribute to the dysbiosis developing, 
the inflammatory response exacerbation and the injury 
of the gastrointestinal mucosa [43]. Thus, dysbiosis in the 
gut commensal microbiota composition, via epigenetic 
regulation mechanisms, has a role not only in IBD patho-
genesis, but also as a risk factor for the development and 
progression of the disease.
Interestingly, epigenetic mechanisms have been evi-
denced to regulate gene expression including miRNAs 
expression, and likewise, miRNAs has shown to affect 
epigenetic mechanisms, by targeting genes encoding 
enzymes, such as DNA methyltransferases (DNMTs), 
HDACs and Histone methyltransferases (HMT). Thus, 
a feedback loop regulates miRNAs and epigenetic 
mechanisms interactions [16, 44–46]. On this subject, 
some authors have found that several miRNAs, asso-
ciated with physiological and pathological conditions, 
can control gene expression establishing, promot-
ing and regulating epigenetic mechanisms. Regard-
ing physiological processes, miR29 and miR140 have 
shown a role in embryogenesis mediated by epigenetic 
modifications. Tuddenham et  al. have described the 
HDAC4 as a target of miR-140, a miRNA expressed in 
cartilage tissues during the mouse embryos develop-
ment [47]. Otherwise, miR-29b has been implicated in 
DNA methylation processes through the regulation of 
Dnmt3a/3b and Ten-Eleven Translocation methylcy-
tosine dioxygenases Tet1/2/3 gene expression, during 
porcine embryogenesis [48]. Furthermore, the down-
regulation of DNMT1 by miR-377 overexpression has 
been associated with senescence and with alterations 
in the promoter methylation level of various genes as 
the Tumor Suppressor Gene p53 [49]. In tumorigen-
esis, low level of miRNAs as miR-137, whose target 
gene is the histone demethylase KDM5B, is associated 
with the increased expression of KDM5B and with cell 
proliferation [50]. In the same way, the Histone-Lysine 
N-Methyltransferase EZH2 is a target of miR-101. In 
Bladder carcinoma cells, miR-101 is found in reduced 
levels correlating with high expression of EZH2 and 
phenotypically, with tumor growth [51]. Addition-
ally, in tumor-associated endothelial cells, VEGF is 
involved in mir-101 downregulation and consequently, 
the EZH2 expression increases promoting angiogen-
esis [52]. Likewise, in colorectal cancer (CRC), includ-
ing IBD-associated CRC, the enzymes DNMT3A and 
DNMT1 evidenced as targets of mir-143 and miR-342, 
respectively, have shown increased expression levels, 
correlating with low levels of miR-143 and miR-342 
and thereby with tumor growth and cell proliferation 
[53, 54]. Thus, the role of the regulation of DNA meth-
ylation and histone acetylation by miRNAs as miR-
185, miR-221, miR-152, miR-200a, among others, has 
been related to alterations in gene expression of sev-
eral genes associated with tumorigenesis processes 
[55–58]. Regarding infection diseases, it is interesting 
to mention that the Hepatitis B virus X protein induces 
low expression levels of miR-101 and thereby altera-
tions in DNA methylation due to the upregulation of 
its target gene DNMT3A. These findings are related 
to carcinogenesis and suggest the role of viral proteins 
in oncogenesis via alterations of miRNAs expression 
associated with epigenetic mechanisms [59]. Related to 
chronic inflammatory conditions and autoimmune dis-
ease, miR-34a has a role in atheroma plaque formation, 
through the regulation of HDAC1 in Hyperhomocyst-
einemia condition  [60]. In Systemic Lupus Erythema-
tosus (SLE), the association of miRNAs dysregulation 
with T cells phenotype alterations has been explained 
by variations in the expression of their target genes 
involved in epigenetic mechanisms, such as DNMTs 
and EZH2 [10, 21, 61].
Therefore, characterization of the roles of epigenet-
ics and miRNAs in CD, and identification of their inter-
actions, could provide useful knowledge which will 
offer a  realistic and practical platform in the generation 
of predictive diagnostic tests, therapies and monitor-
ing. The aims of the present study are to identify in sil-
ico the relationship among miRNAs and genes encoding 
enzymes associated with epigenetic and post-transla-
tional modifications in CD and to determine their impact 
in the development of the disease and the susceptibility 
to complications.
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Methods
Identification of miRNAs found overexpressed in CD 
patients’ tissues
miRNAs associated with CD were identified using HMDD 
databases and original papers from Web of Science and 
Pubmed. The search terms used were “Crohn’s disease” and 
“microRNAs.” The searching was performed with the help 
of the R Bibliometrix package.
Selection of miRNAs found overexpressed in tissue 
samples from CD patients that regulate enzymes 
associated with epigenetic and post‑translational 
modifications
In order to identify miRNAs overexpressed in CD-affected 
tissues and that regulate the expression of enzymes associ-
ated with epigenetic and post-translational modifications, 
110 papers that reported the upregulation of 190 miRNAs 
in CD patients were cross-indexed with 1,544 miRNAs that 
interact with mRNAs for enzymes related to epigenetic and 
post-translational modifications. To identify miRNAs that 
regulate epigenetic and post-translational modifiers was 
used mirPath v.3 (acetylation, bromination, formylation, 
gamma-carboxyglutamic acid, hydroxylation, lipoylation, 
LTQ, methylation, N-linked glycosylation, N6-carboxyly-
sine, nitration, O-linked glycosylation, oxidation, phospho-
rylation, pyridoxal phosphate, pyrrolidone, carboxylic acid, 
pyruvate, retinal protein, S-nitrosylation and sulfation). The 
identified miRNAs-target mRNA interactions are validated 
from specific, as well as high-throughput experiments. The 
results obtained from both databases were compared to 
obtain the miRNAs dataset associated with epigenetic and 
post-translational modifications.
Construction of functional interaction network of enzymes 
associated with epigenetic and post‑translational 
modifications, whose expression is regulated by miRNAs 
overexpressed in CD
Protein–protein biological interaction of identified 
enzymes associated with epigenetic and post-translational 
modifications and regulated by miRNAs overexpressed in 
CD, were analyzed using String v11 database. Physical as 
well as functional interactions with medium confidence 
of 0.4 were analyzed in order to perform the interactive 
network. In addition, proteins were classified according 
to “Gene Ontology (GO) Biological Process” distribution 
option of String v11. The analysis was performed focused 
on mainly epigenetic modifiers.
Results
miRNAs identified to be overexpressed in Crohn’s 
diseases interact with mRNAs for enzymes associated 
with epigenetic and post‑translational modifications: 
integrative analysis of miRNAs associated with CD
A total of 190 miRNAs were identified to be associated 
with CD (Additional file 1: Table S1), which were cross-
indexed with 1,544 miRNAs that interact with mRNAs 
for enzymes related to epigenetic and post-translational 
modifications. This yielded 34 miRNAs that were pre-
sent on both lists (Additional file  2: Table  S2). From 
the 34 selected miRNAs, 26 were identified to interact 
with mRNAs for epigenetic modifiers (Additional file 2: 
Table S2).
From the 190 miRNAs identified to be associated 
with CD, hsa-miR-30d-5p [3] regulates the largest 
number of mRNAs for enzymes associated with epi-
genetic and post-translational modifications, a total 
of 20 mRNAs: Ubiquitin-Conjugating Enzyme E2J 1 
(UBE2J1) [62], Catechol-O-methyltransferase (COMT) 
[63], Ubiquitin-Conjugating Enzyme E2R 2 (UBE2R2) 
[64], Methil-CpG-Binding Protein 2 (MECP2) [65], 
DNA Methyltransferase 3A (DNMT3A)  [66], Nuclear 
Receptor Binding SET Domain Protein 1 (NSD1) [67], 
UBE2D2, KMT2D, UBE2K, RNMT, MTR, KMT2C, 
SETD7, SETD3, UBE2D3, SETD1B, SUV39H2, 
KMT2A, CTLA4 and EZH2. In addition, hsa-let-7b-5p 
[68] regulates a total of 17 mRNAs: NSD1, CA12, 
UBE2D2, KMT2D, TRMT1, RNMT, KMT2E, NSUN2, 
SP1, UBE2A, UBE2Q1, UBE2D3, SUV39H2, TYMS, 
TRMT13, PRMT1 and EZH2, which are associated 
with epigenetic and post-translational modifications. 
Furthermore, hsa-miR-181d [69] downregulates 12 
mRNAs associated with epigenetic and post-transla-
tional modifications: UBE2J1, UBE2W, MECP2, RNMT, 
KMT2C, KMT2E, SP1, UBE2D3, CARM1, SUV39H2, 
KMT2A, MGMT. Network shows the 26 miRNAs 
interacting with their target mRNAs associated with 
epigenetic modifiers (Fig. 1).
Protein–protein interaction network of enzymes 
associated with epigenetic and post‑translational 
modifications, whose expression is regulated by miRNAs 
involved in Crohn’s disease
Biological interactions of identified enzymes associated 
with epigenetic and post-translational modifications, reg-
ulated by miRNAs involved in CD, were analyzed using 
String v11 database. From the 70 identified enzymes 
associated with PTMs, 63 show a protein–protein inter-
action network with 297 edges, and average node degree 
of 8.49, average local clustering coefficient of 0.654, and 
PPI enrichment p value < 1.0e−16.
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According to biological processes, the proteins 
were classified as follows (Additional file  3: Table  S3): 
54,3 percent of proteins were related to methylation 
(GO:0032259) (TRMT10C, NSUN2, RNMT, METTL3, 
METTL16, TRMT1, DIMT1, TRMT13, DPH5, SETD3, 
ASH1L, NSD1, KMT2A, PRMT1, SMYD2, PRDM2, 
PRMT5, SETD7, KMT2C, KMT2D, KMT2E, SETD1B, 
SETD1A, SETD2, CARM1, SUV39H2, DNMT3A, 
EZH2, DNMT3B, MECP2, METTL15, MGMT, TYMS, 
MTR, COMT, TYW3, CMTR2, and PCMT1); 30% were 
related to histone modification (GO:0016570) (MECP2, 
SUV39H2, CARM1, EZH2, PRMT5, SETD7, SETD2, 
KMT2D, PRDM2, SMYD2, PRMT1, NSD1, SETD3, 
ASH1L, KMT2A, KMT2E, KMT2C, SETD1B, SETD1A, 
UBE2A and UBE2E1); 24,3% were related to protein 
ubiquitination (GO:0016567) (UBE2A, UBE2C, UBE2K, 
UBE2H, UBE2E1, UBE2S, UBE2D3, UBE2W, UBE2R2, 
UBE2D1, UBE2J2, UBE2D2, UBE2Z, UBE2J1, UBE2Q1, 
SIAH1 and UBE2L3); 11,4% were related to regulation 
of cell cycle process (GO:0010564) (KMT2E, PRMT1, 
SETD2, CARM1, EZH2, MECP2, UBE2C, PRMT5); 
18,6% were related to regulation of immune system 
process (GO:0002682) (METTL3, DNASE1, FCGR2B, 
CTLA4, FCGR2A, PTPN22, PRMT1, KMT2A, KMT2E, 
KMT2D, SETD1A, KMT2C, UBE2K); 60% were asso-
ciated with protein metabolic process (GO:0019538) 
(PCMT1, UBE2A, UBE2C, UBE2K, UBE2H, UBE2E1, 
UBE2S, UBE2D3, UBE2W, UBE2R2, UBE2D1, UBE2J2, 
UBE2D2, UBE2Z, UBE2J1, UBE2Q1, SIAH1, UBE2L3, 
MOGS, GANAB, MECP2, DPH5, SUV39H2, CARM1, 
PRMT5, EZH2, SETD7, PRDM2, NSD1, SMYD2, 
SETD2, KMT2D, PRMT1, SETD3, KMT2C, SETD1A, 
KMT2A, SETD1B, KMT2E, ASH1L, PDK3 and 
PTPN22) and 57,1% were related to nucleic acid meta-
bolic process (GO:0090304) (CMTR2, UBE2L3, UBE2W, 
UBE2D3, UBE2A, TYMS, TRMT13, MGMT, DNMT3B, 
MECP2, SP1, DNMT3A, SUV39H2, CARM1, PRMT5, 
EZH2, SETD7, PRDM2, NSD1, SMYD2, SETD2, 
KMT2D, SETD3, KMT2C, SETD1A, KMT2A, SETD1B, 
KMT2E, ASH1L, TYW3, METTL15, TREX1, DNASE1, 
TRMT10C, TRMT1, NSUN2, RNMT, DIMT1, METTL3 
and METTL16) (Fig. 2). Analysis allowed the identifica-
tion of epigenetic modifiers (Additional file 3: Table S3).
Discussion
The study of the interaction of miRNAs regulation 
pathways, mRNA targets and epigenetic mechanisms 
associated with diseases, can generate valuable knowl-
edge about the subjacent molecular mechanisms of the 
pathologies and its chronicity, as well as the implication 
of genes variants in diseases. Furthermore, the identifi-
cation of miRNAs profiles, strongly associated with dis-
eases susceptibility and pathogenesis, could serve as a 
platform to the development of novel therapies with spe-
cific targets, and diagnostic markers to identify not only 
those affected, but those at-risk individuals prior to clini-
cal onset of the disease [3, 8, 11, 68].
Fig. 1 miRNA‑Target mRNA network showing the interaction of miRNAs involved in Crohn’s disease and their Target mRNA of proteins associated 
with epigenetic mechanisms. Green box nodes represent miRNAs and blue box nodes represent mRNAs
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In the present work, we analyzed the gene expression 
profile regulated by identified miRNAs associated with 
CD. The analysis showed 190 miRNAs overexpressed 
in Crohn’s disease and their interactions with enzymes 
associated with epigenetic and post-translational modifi-
cations. From the identified 190 miRNAs associated with 
CD (Additional file 1: Table S1), 34 miRNAS were found 
to interact with mRNAS encoding enzymes that catalyze 
epigenetic and post-translational modifications (Addi-
tional file  2: Table  S2), of which 26 interact with epige-
netic modifiers (Fig. 1).
In addition, to explore the biological relevance of 
miRNAs in epigenetic mechanisms related to Crohn’s 
disease, we analyze the landscape of miRNAs that have 
been shown experimentally greater relative abundance in 
patients with Crohn’s disease and that interact with genes 
encoding enzymes that perform epigenetic modifica-
tions, since these mechanisms constitute ways of immu-
nological, metabolic and cell cycle processes regulation 
(Fig. 2). Although the universe of mechanisms of action 
mediated by miRNAs is quite wide, here we associate a 
high expression of miRNAs with a decrease in the effi-
ciency of the translation of miRNAs’ target mRNAs.
According to the data obtained, miRNAs identified 
overexpressed in CD associated with epigenetic mecha-
nisms are involved in the regulation of several biological 
processes closely related to immunological and tumo-
rigenic processes (Fig. 2). In this regard, dysregulation of 
Fig. 2 Functional interaction network of enzymes associated with epigenetic and post‑translational modifications, whose expression is regulated 
by miRNAs involved in Crohn’s disease. Proteins were classified by String v11 software according to “(GO) Biological Process” distribution option. 
Each node represents all the proteins produced by a single protein‑coding gene locus. Red nodes correspond to proteins involved in methylation 
(GO:0032259), blue nodes to histone modification (GO:0016570), dark green nodes to protein metabolic process (GO:0019538), light green nodes 
to nucleic acid metabolic process (GO:0090304), aquamarine nodes to protein ubiquitination (GO:0016567), yellow nodes to regulation of cell cycle 
process (GO:0010564) and pink nodes to regulation of immune system process (GO:0002682), respectively. Edges represent protein–protein action 
type associations
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Histone-lysine N-methyltransferase SUV39H2 (Suppres-
sor of variegation 3–9 homolog 2) expression, whose 
encoding gene is a target of miRNAS upregulated in CD, 
hsa-let-7b-5p, hsa-let-7g-5p, hsa-miR-30c-5p, hsa-miR-
30d-5p, hsa-miR-98, hsa-miR-181d (Fig. 1), has been evi-
denced to be involved in TGF beta-induced epithelial to 
mesenchymal transition, migration of cancer cells, car-
cinogenesis and metastasis [70]. It is interesting to men-
tion that the role of TGF-beta in CD has been previously 
evidenced  [71, 72]. TGF-beta is a regulatory cytokine 
secreted by intestinal epithelial cells and mucosal T cells 
that shows anti-inflammatory and protecting functions, 
decreasing local immune responses to luminal antigens, 
enhancing barrier function and promoting the produc-
tion of secretory immunoglobulin A (IgA) [71, 72]. Thus, 
miRNAs dysregulation in CD could mediate epigenetic 
mechanisms implicated in TGF-beta signaling pathways 
thereby generating inflammation and carcinogenesis.
SUV39H2 downregulation has been also associated 
with autoimmune diseases. Decreased expression levels 
of SUV39H2 and reduction of global H3 lysine 9 meth-
ylation has been evidenced in CD4+  T cells from Latent 
autoimmune diabetes patients [73]. These data correlate 
with the miRNAs pattern of CD patients found in this 
study (Fig.  1). The upregulation of miRNAs whose tar-
get gene is SUV39H2 suggests a repression of SUV39H2 
expression that can be involved in CD autoimmune 
pathogenesis.
Regarding T lymphocytes differentiation, Methyl-
CpG binding protein 2 (MECP2), whose encoding gene 
expression is regulated by miRNAs found overexpressed 
in CD patients, such as hsa-miR-30c-5p, hsa-miR-124-3p, 
hsa-miR-30d-5p and hsa-miR-181d (Fig.  1), has been 
evidenced to bind methylated DNA, inducing transcrip-
tional repression of target genes. Interestingly, MECP2 is 
essential for sustaining Foxp3 stable expression in Regu-
latory T cells (Tregs), as well as, Tregs lineage function 
during inflammation. Li et  al. have described that in 
response to TCR activation and inflammatory cytokine 
signaling, conserved non-coding sequence 2 region 
(CNS2) of foxp3 locus recruits MECP2. MECP2 inter-
acts with cAMP responsive element binding protein 1 
(CREB1) and as a consequence rescues foxp3 transcrip-
tion through local histone H3 acetylation. Thus, MECP2 
induces in Tregs, resistance to inflammation-induced 
silencing of foxp3 via an epigenetic mechanisms [74]. 
In this regard, the high levels of miRNAs that regulate 
MECP2 encoding gene expression in CD could explain in 
part the phenotype of these patients and might be inter-
esting targets in the generation of novel treatments for 
autoimmune and inflammatory diseases, including CD.
DNA methyltransferases (DNMTs) association with 
autoimmune diseases has been evidenced in patients 
affected by multiple sclerosis (MS). The DNA meth-
ylation status in immune cells and brain tissues from 
MS samples have shown alterations [75]. In the present 
study, miRNAs found upregulated in CD affected tis-
sues, such as hsa-miR-192-5p, hsa-miR-30d-5p, hsa-
miR-1, hsa-miR-101-3p and hsa-miR-375, are involved 
in gene expression regulation of DNMT3A, DNMT3B 
(Fig.  1). Increased levels of these enzymes have been 
described during CD4+ T cells polarization toward T 
helper 2 (Th2) phenotype compared with their expres-
sion in naïve or Th1 cells. DNMT3A has been also associ-
ated with DNA methylation at the Il13 locus, repressing 
Il13 expression in Th2 cells and thereby avoiding strong 
inflammatory allergic reactions [76]. Therefore, the regu-
lation of DNMT3A expression by miRNAs in CD might 
be associated with CD4+ T cells polarization toward 
pro- inflammatory phenotypes, able to promote exacer-
bated inflammatory conditions.
Histone-Lysine N-Methyltransferases KMT2D, 
KMT2C, KMT2E, KMT2A are regulated by several 
miRNAs overexpressed in CD-affected tissues such 
as hsa-let-7b-5p, hsa-let-7g-5p, hsa-miR-146b-5p, 
hsa-miR-142-5p, hsa-miR-107, hsa-miR-342-3p, hsa-
miR-30d-5p, hsa-miR-1, hsa-miR-30c-5p, hsa-miR-98, 
hsa-miR-196a-5p, hsa-miR-484, hsa-miR-130b-5p, hsa-
miR-182-5p, hsa-miR-192-5p, hsa-miR-181d and hsa-
miR-193a-3p (Fig.  1). KMT2 enzymes methylate H3K4 
and this modification has been evidenced to have a role 
in tumorigenesis [77]. Low levels of KMT2D induce car-
cinogenesis via epigenetic modifications, repressing the 
expression of Period Circadian Regulator 2 (PER2) gene, 
which regulates tumor-promoting glycolytic genes [78]. 
According to these data, mutations in KMT2D gene have 
been identified in ulcerative colitis-associated colorectal 
neoplasia [79]. On the other hand, the Histone-Lysine 
N-Methyltransferase EZH2, whose gene expression is 
regulated by various miRNAS upregulated in CD, such as 
hsa-miR-484, hsa-miR-124-3p, hsa-let-7b-5p, hsa-miR-
30d-5p, hsa-miR-98 and hsa-miR-101-3p (Fig. 1), plays an 
important role in maintaining intestinal barrier integrity 
and immune homeostasis in IBD through the regulation 
of TNFα signaling pathways, among other inflamma-
tory molecules [80, 81]. Consistent with the upregulated 
miRNAs showed in the present study, EZH2 expression 
in IBD colonic epithelial cells has been found downreg-
ulated. Thus, the study of EZH2 regulation by miRNAs 
could generate a new target treatments aim to ameliorate 
the EZH2 expression in CD patients in order to preserve 
the intestinal epithelial health.
Additionally, Histone-Lysine N-Methyltransferases 
SETD2, SETD3, SETD7, SETD1A, SETD1B gene 
expression is regulated by miRNAs overexpressed 
in CD, such as hsa-miR-21-5p, hsa-miR-142-5p, 
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hsa-miR-10b-5p, hsa-miR-30c-5p, hsa-miR-484, 
hsa-miR-376c, hsa-miR-342-3p, hsa-miR-455-3p, 
hsa-miR-30d-5p, hsa-miR-107, hsa-miR-182-5p and 
hsa-miR-375. These data correlate with the reduced 
level of SETD2 observed in IBD patients. Lack of 
SETD2 expression in intestinal tissues is associated 
with decreased number of mucus-producing gob-
let cells, immune cells infiltrate, high levels of pro-
inflammatory cytokines and chemokines, loss of the 
mucosal barrier integrity and epithelium inflamma-
tory injury that can progress toward high-grade dys-
plasia. These alterations are explained in part, by the 
SETD2 induced regulation of gene expression related 
to apoptotic pathways, inflammatory response and 
mainly with oxidative stress [82]. Thus, these data 
suggest that normal expression levels of SETD2 could 
avoid IBD pathogenesis mediating oxidative stress reg-
ulation via epigenetic mechanisms. Moreover, SETD7 
downregulation has been associated with tumorigen-
esis mediated by epigenetic modifications [83, 84]. 
These findings show the relevance of Histone-Lysine 
N-Methyltransferases regulation by miRNAs overex-
pressed in CD, in IBD carcinogenesis and inflamma-
tory processes.
Regarding to miRNAs found in this research, over-
expressed in CD-affected mucosa, and associated 
with bacterial invasion of epithelial cells, such as 
hsa-miR-140-5p, hsa-miR-124-3p, hsa-let-7g-5p, 
hsa-miR-142-3p, hsa-miR-21-5p, hsa-let-7b-5p, hsa-
miR-196a-5p and hsa-miR-182-5p, studies have dem-
onstrated that gut microbiota composition could alter 
local miRNAs profile and epigenetic mechanisms, 
providing a suitable setting for IBD [85–87]. In recent 
years, it has been also described that miRNAs can 
mediate host-microbiota interactions and can affect 
the composition of gut microbiota [88]. Likewise, 
microbiota composition affects the DNA methylation 
pattern in intestinal epithelial cells [89]. Addition-
ally, it is known that in neonates, the diversified and 
balanced microbiota composition is essential for the 
development and maturation of the immune system. 
The reviewed data support the evidence that the inter-
action of genetic factors, miRNAs, epigenetic modi-
fications, immunological pathways and microbiota 
composition regulates the intestinal health. Thus, the 
dysbiosis, characterized by a decreasing in the preva-
lence of resident obligate anaerobic bacteria, and an 
increasing in relative abundance of facultative anaer-
obes, such as Enterobacteriaceae, found in the intes-
tinal mucosa of CD patients, favors the production of 
metabolites that modulate signaling pathways involved 
in IBD pathogenesis and Colorectal carcinogenesis 
[86, 87, 89].
Conclusion
The identification and analysis of miRNAs found overex-
pressed in CD-affected tissues, and their association with 
epigenetic mechanisms, have shown the influence of the 
interaction of miRNAs regulation, enzymes associated 
with epigenetic modifications and gut commensal micro-
biota composition, in CD pathogenesis processes, such as 
alterations in T cells polarization, cell cycle, carcinogen-
esis, oxidative stress and intestinal barrier integrity main-
tenance. These data shed light to the study and design of 
therapeutic approaches in CD, based in the regulation of 
tissue-specific miRNAs and enzymes associated with epi-
genetic modifications.
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